CanSino Biologics’ inhaled vaccine must go through clinical trials for approval. A late-stage human trial involving 13,000 participants was registered on Clinicaltrials.gov last month. Photo: Reuters
CanSino Biologics’ inhaled vaccine must go through clinical trials for approval. A late-stage human trial involving 13,000 participants was registered on Clinicaltrials.gov last month. Photo: Reuters

Could CanSino’s inhaled coronavirus vaccine booster be a quick, needle-free option?

  • Study finds Chinese vaccine induces a higher level of immune response than a Sinovac booster for those vaccinated with two Sinovac shots
  • Inhaled vaccines imitate natural Covid-19 infection, targeting the nose, throat and lungs entry points for a localised immune response

Topic |   Coronavirus pandemic
CanSino Biologics’ inhaled vaccine must go through clinical trials for approval. A late-stage human trial involving 13,000 participants was registered on Clinicaltrials.gov last month. Photo: Reuters
CanSino Biologics’ inhaled vaccine must go through clinical trials for approval. A late-stage human trial involving 13,000 participants was registered on Clinicaltrials.gov last month. Photo: Reuters
READ FULL ARTICLE